Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: The step-wise randomized study

Endocrine Practice

Volumn 17, Issue 5, 2011, Pages 727-736

  Meneghini, Luigi ^a   Mersebach, Henriette ^b   Kumar, Sudhesh ^c   Svendsen, Anne Louise ^b   Hermansen, Kjeld ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BOLUS INJECTION; COLON CANCER; COMPARATIVE STUDY; DIABETES CONTROL; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PNEUMONIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

AGED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; INSULIN, SHORT-ACTING; MALE; MIDDLE AGED;

EID: 80054079094     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP10367.OR     Document Type: Article

References (22)

1. UK Prospective Diabetes Study. V. Characteristics of newly presenting type 2 diabetic patients: Estimated insulin sensi-tivity and islet 4-cell function. Multi-centre study. Diabet Med. 1988;5:444-448.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
3. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
4. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabe-tes. Clin Ther. 2006;28:1569-1581.
5. Blonde L, Merilainen M, Karwe V, Raskin P; TIRATE Study Group. Patient-directed titration for achieving gly-caemic goals using a once-daily basal insulin analogue: An assessment of two different fasting plasma glucose tar-gets - The TITRATE study. Diabetes Obes Metab. 2009;11: 623-631.
6. Holman RR, Thorne KI, Farmer AJ, et al; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357: 1716-1730.
7. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insu-lin-naive people with type 2 diabetes. Diabetologia. 2008; 51:408-416.
8. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough-what next? Diabetes Metab Res Rev. 2007;23:257-264.
9. Hirsch IB, Yuan H, Campaigne BN, Tan MH. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients. Endocr Pract. 2009;15:343-348.
10. Gerich JE. Clinical significance, pathogenesis, and man-agement of postprandial hyperglycemia. Arch Intern Med. 2003;163:1306-1316.
11. Gerich JE, Odawara M, Terauchi Y. The rationale for paired pre- and postprandial self-monitoring of blood glu-cose: The role of glycemic variability in micro- and macro-vascular risk. Curr Med Res Opin. 2007;23:1791-1798.
12. Halbron M, Jacqueminet S, Sachon C, Bosquet F, Hartemann-Heurtier A, Grimaldi A. Insulin therapy for type 2 diabetes: Premixed or basal-prandial? Diabetes Metab. 2007;33:316-320.
13. Jang HC, Guler S, Shestakova M, PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensifica-tion with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract. 2008; 62:1013-1018.
14. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: Prandial premixed (insulin lispro protamine suspension/lis-pro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008;31:20-25.
15. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA, Orals Plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in type 2 diabetes: A comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab. 2008;10:1178-1185.
16. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and last amended by the 59th WMA General Assembly, Seoul, October 2008.
17. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1). Step 4 ver-sion. June 10, 1996.
18. Bergenstal RM, Johnson M, Powers MA, et al. Adjust to target in type 2 diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 2008;31:1305-1310.
19. Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract. 2011;17:395-403
20. Hermansen K, Mortensen LS. Bodyweight changes asso-ciated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30:1127-1142.
21. Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensifi-cation of insulin therapy in overweight type 2 diabetes patients: The PREDICTIVE BMI clinical trial. Diabet Med. 2008;25:916-923.
22. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 dia-betes: A meta-analysis. Diabetes Res Clin Pract. 2008;81: 184-189.